Resveratrol Modulation of Protein Expression in parkin-Mutant Human Skin Fibroblasts: A Proteomic Approach

Table 6

List of differentially expressed proteins identified by MS/MS in P1 and P1-Res-treated samples.

Spot number	Swiss-Prot accession number	Protein name	Gene name	Mascot score		Sequence coverage MS	Sequence coverage MS/MS	Peptides	Fold change P1 Res/P1	value	Instrument
				PMF	MS/MS
Spot 21	Q14697	Neutral alpha-glucosidase AB (GANAB)	GANAB	265	137	37%	3%	K.AEKDEPGAWEETFK.T; K.MMDYLQGSGETPQTDVR.W + oxidation (M)	1.9		MALDI-TOF/TOF
Spot 22	P18206	Vinculin (VINC)	VCL	/	105	/	10%	R.WIDNPTVDDR.G; R.VMLVNSMNTVK.E + oxidation (M); K.MTGLVDEAIDTK.S + oxidation (M); K.QVATALQNLQTK.T; K.AQQVSQGLDVLTAK.V; R.DPSASPGDAGEQAIR.Q; R.GILSGTSDLLLTFDEAEVR.K; R.GILSGTSDLLLTFDEAEVR.K; K.LLAVAATAPPDAPNREEVFDER.A	1.6		Esi-Trap
Spot 23	P42224	STAT1 (STAT1)	STAT1	86	85	24%	4%	K.YLYPNIDKDHAFGK.Y; K.QDWEHAANDVSFATIR.F	2.2		MALDI-TOF/TOF
Spot 24	P02511	Alpha-crystallin B chain (CRYAB)	CRYAB	103	79	12%	11%	R.QDEHGFISR.E; R.RPFFPFHSPSR.L	−2.3		MALDI-TOF/TOF
Spot 25	P63244	Guanine nucleotide-binding protein subunit beta-2-like 1 (GBLP)	GNB2L1	97	84	38%	6%	R.VWQVTIGTR.-R.DETNYGIPQR.A	−1.9		MALDI-TOF/TOF
Spot 26	P61163	Alpha-centractin (ACTZ)	ACTR1A	78	87	23%	4%	K.AQYYLPDGSTIEIGPSR.F	−1.6		MALDI-TOF/TOF
Spot 27	P61160	Actin-related protein 2 (ARP2)	ACTR2	61	151	20%	10%	K.HLWDYTFGPEK.L; R.GYAFNHSADFETVR.M; K.HIVLSGGSTMYPGLPSR.L + oxidation (M)	−1.7		MALDI-TOF/TOF
Spot 28	P00367/Q15654	Glutamate dehydrogenase 1, mitochondrial (DHE3)/thyroid receptor-interacting protein 6 (TRIP6)	GLUD1/TRIP6	84/123	91/73	29%/39%	3%/8%	K.MVEGFFDR.G; R.DDGSWEVIEGYR.A; /; R.GTPGPPPAHGAALQPHPR.V; R.VNFCPLPSEQCYQAPGGPEDR.G	−2.1		MALDI-TOF/TOF
Spot 29	Q06830	Peroxiredoxin-1 (PRDX1)	PRDX1	/	47	/	29%	R.TIAQDYGVLK.A; K.ATAVMPDGQFK.D + oxidation (M); R.LVQAFQFTDK.H; R.QITVNDLPVGR.S	2		ESI-Trap
Spot 30	P52907	F-actin-capping protein subunit alpha-1 (CAZA1)	CAPZA1	59	109	34%	9%	R.LLLNNDNLLR.E; K.FITHAPPGEFNEVFNDVR.L	1.8		MALDI-TOF/TOF
Spot 31	P40925	Malate dehydrogenase, cytoplasmic (MDHC)	MDH1	58	173	18%	6%	K.GEFVTTVQQR.G; K.FVEGLPINDFSR.E	1.7		MALDI-TOF/TOF
Spot 33	P78417	Glutathione S-transferase omega I (GSTO1)	GSTO1	102	137	36%	17%	R.FCPFAER.T; R.HEVININLK.N; K.GSAPPGPVPEGSIR.I; K.EDYAGLKEEFR.K	−1.6		MALDI-TOF/TOF
Spot 34	P09960	Leukotriene A-4 hydrolase (LKHA4)	LTA4H	66	42	17%	5%	R.TLTGTAALTVQSQEDNLR.S; R.MQEVYNFAINNSEIR.F + oxidation (M)	−1.6		MALDI-; TOF/TOF
Spot 35	P07900	Heat-shock protein HSP 90-alpha (HS90A)	HSP90AA1	/	70	/	12%	K.DQVANSAFVER.L; K.ADLINNLGTIAK.S; R.ELISNSSDALDK.I; K.EDQTEYLEER.R; K.EGLELPEDEEEK.K; R.GVVDSEDLPLNISR.E; R.NPDDITNEEYGEFYK.S; K.TKPIWTRNPDDITNEEYGEFYK.S	−1.5		Esi-Trap
Spot 37	P30086	Phosphatidylethanolamine-binding protein 1 (PEBP1)	PEBP1	61	177	28%	22%	K.LYTLVLTDPDAPSR.K; K.NRPTSISWDGLDSGK.L; R.YVWLVYEQDRPLK.C	2		MALDI-; TOF/TOF
Spot 39	P61160	Actin-related protein 2 (ARP2)	ACTR2	61	151	20%	10%	K.HLWDYTFGPEK.L; R.GYAFNHSADFETVR.M; K.HIVLSGGSTMYPGLPSR.L + oxidation (M)	1.7		MALDI-; TOF/TOF
Spot 41	P30086	Phosphatidylethanolamine-binding protein 1 (PEBP1)	PEBP1	187	238	67%	22%	K.LYTLVLTDPDAPSR.K; K.NRPTSISWDGLDSGK.L; R.YVWLVYEQDRPLK.C	−1.6		MALDI-TOF/TOF
Spot 42	P13010	X-ray repair cross-complementing protein 5 (XRCC5)	XRCC5	89	110	12%	4%	R.LFQCLLHR.A; R.HIEIFTDLSSR.F; R.ANPQVAFPHIK.H	1.8		MALDI-TOF/TOF
Spot 44	P30041	Peroxiredoxin-6 (PRDX6)	PRDX6	122	244	61%	16.5%	R.NFDEILR.V; K.LPFPIIDDR.N; M.PGGLLLGDVAPNFEANTTVGR.I	−1.6		MALDI-TOF/TOF
Spot 45	P11142	Heat-shock cognate 71 kDa protein (HSP7C)	HSPA8	/	178	/	28%	K.VEIIANDQGNR.T; R.FEELNADLFR.G; R.FDDAVVQSDMK.H; K.NSLESYAFNMK.A; K.CNEIINWLDK.N; K.NSLESYAFNMK.A + oxidation (M); K.SQIHDIVLVGGSTR.I; R.TTPSYVAFTDTER.L; K.SFYPEEVSSMVLTK.M; K.NQVAMNPTNTVFDAK.R; R.IINEPTAAAIAYGLDK.K; K.STAGDTHLGGEDFDNR.M; K.TVTNAVVTVPAYFNDSQR.Q; K.TVTNAVVTVPAYFNDSQR.Q; K.SINPDEAVAYGAAVQAAILSGDK.S	2.1		MALDI-TOF/TOF
Spot 46	P04792	Heat-shock protein beta 1 (HSPB1)	HSPB1	127	171	51%	13%	R.LFDQAFGLPR.L; K.LATQSNEITIPVTFESR.A	1.6		MALDI-TOF/TOF
Spot 47	P09936	Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCHL1)	UCHL1	86	220	49%	19%	R.LGVAGQWR.F; R.MPFPVNHGASSEDTLLK.D + oxidation (M); K.NEAIQAAHDAVAQEGQCR.V	1.7		MALDI-TOF/TOF
Spot 48	P15311	Ezrin (EZRI)	EZR	111	134	25%	4%	K.IGFPWSEIR.N; R.IQVWHAEHR.G; K.KAPDFVFYAPR.L	−1.7		MALDI-TOF/TOF
Spot 49	P29401	Transketolase (TKT)	TKT	139	222	25%	7%	R.VLDPFTIKPLDR.K; R.TVPFCSTFAAFFTR.A; R.FIECYIAEQNMVSIAVGCATR.N	−1.5		MALDI-TOF/TOF
Spot 50	P42704	Leucine-rich PPR motif-containing protein, mitochondrial (LPPRC)	LRPPRC	109	37	15%	1%	K.SNTLPISLQSIR.S; K.VIEPQYFGLAYLFR.K	−2.1		MALDI-TOF/TOF
Spot 51	P23526	Adenosylhomocysteinase (SAHH)	AHCY	/	84	/	10%	K.VPAINVNDSVTK.S; K.ALDIAENEMPGLMR.M + oxidation (M); K.ALDIAENEMPGLMR.M + 2 oxidation (M); R.ATDVMIAGKVAVVAGYGDVGK.G + oxidation (M)	−1.7		Esi-Trap
Spot 52	P07954	Fumaratehydratase, mitochondrial (FUMH)	FH	66	158	18%	5%	R.IEYDTFGELK.V; R.IYELAAGGTAVGTGLNTR.I	−1.9		MALDI-TOF/TOF

Spot numbers match those reported in the representative 2-DE images shown in Figure 3. Accession number in Swiss-Prot/UniprotKB (http://www.uniprot.org/). Fold change (P1 resveratrol-treated cells versus P1 cells) was calculated dividing the average of %V P1 resveratrol-treated cells by the average of %V P1 cells of three independent experiments. t-test was performed by GraphPad v4.0 software to determine if the relative change was statistically significant (); ; ; .